Want to impress Novartis' CEO? Don't do it in PowerPoint

Novartis ($NVS) CEO Joe Jimenez (photo) tells the New York Times a few things: He's more patient than he used to be. He's learned how to open the door to bad news. And he's not one to compliment a 75-page PowerPoint presentation. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.